Twenty-seven patients with genetically confirmed nonclassical congenital adrenal hyperplasia (NCCAH) achieved mean final adult heights only 0.33 standard deviations below population norms, despite one-third developing central precocious puberty. Height measurements at diagnosis and pubertal onset emerged as the strongest predictors of final stature, with mutation subtype showing no significant impact on growth outcomes. This finding challenges the conventional narrative that NCCAH inevitably compromises adult height. The condition, caused by partial 21-hydroxylase deficiency, has historically been associated with accelerated early growth followed by premature growth plate closure and stunted final height. However, these results suggest that with appropriate monitoring and selective intervention—seven patients received GnRH analogs—height outcomes can remain within acceptable ranges. The study's strength lies in its genetic confirmation of all cases and long-term follow-up through final adult height, addressing previous research limitations. However, the small cohort size and single-center design limit generalizability. For families facing NCCAH diagnosis, this data provides reassurance that modern management approaches can preserve growth potential, though early detection and height tracking remain crucial for optimal outcomes.